Top Markets
#1 Akedo Akedo +59.62%
#2 Glidr Glidr +51.75%
#3 DOVU DOVU +49.64%
#4 Cross Cross +40.87%
#5 OVERTAKE OVERTAKE +34.07%
#6 Black Phoenix Black Phoenix +33.88%
#7 Velvet Velvet +33.26%
#8 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.83%
#9 Cap Cap +15.68%
#10 Bitway Bitway +11.60%
Coin of the day
Akedo Akedo
Settings
Language
ENGLISH
Currency
USD
Theme
Valion Bio, Inc. Valion Bio, Inc.

Valion Bio, Inc.

VBIO
Rank in Stocks #38930
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead... Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Share Price
$0.1818
Market Cap
$752.91K
Change (1 day)
6.44%
Change (1 year)
-94.81%
Country
US
Trade Valion Bio, Inc. (VBIO)

Category

Healthcare
P/E ratio for Valion Bio, Inc. (VBIO)
P/E ratio as of 2026 TTM: 0
According to Valion Bio, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Valion Bio, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.